Ivonescimab Extends Overall Survival Over Pembrolizumab in PD-L1-Positive Advanced Lung Cancer
A prespecified interim analysis of the phase 3 HARMONi-2 trial shows ivonescimab achieved median overall survival of 30.8 months versus ...
Tag: WCLC 2026
POPULAR NEWS
-
Pistachio shells turned into glowing carbon dots with antioxidant and antibacterial power in five minutes
-
Hong Kong’s record longevity hides a birthplace gap in later-life survival
-
Ivonescimab Extends Overall Survival Over Pembrolizumab in PD-L1-Positive Advanced Lung Cancer
-
Precision priming, not spraying, may unlock salicylic acid for crops